Incidence of Diabetes in Colorectal Cancer Survivors

Journal of the National Cancer Institute

Volumn 108, Issue 6, 2016, Pages

  Singh, Simron ^a   Earle, Craig C ^a,b,c   Bae, Sandy J ^a   Fischer, Hadas D ^b   Yun, Lingsong ^b   Austin, Peter C ^b,c   Rochon, Paula A ^b,c,d,e   Anderson, Geoffrey M ^b,c,e   Lipscombe, Lorraine ^b,d,e  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CANADA; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CEREBROVASCULAR ACCIDENT; COLORECTAL CANCER; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; METASTASIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; ADULT; AGED; CASE CONTROL STUDY; COLORECTAL TUMOR; COMPARATIVE STUDY; COMPLICATION; FACTUAL DATABASE; INCIDENCE; MIDDLE AGED; ODDS RATIO; ONTARIO; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SURVIVOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; ODDS RATIO; ONTARIO; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVORS;

EID: 84977112031     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv402     Document Type: Article

References (68)

1. American Cancer Society. Colorectal Cancer Facts & Figures 2014-2016. In. Atlanta: American Cancer Society; 2014.
2. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. In. Toronto, ON; 2014.
3. National Cancer Institute. DevCan: Probability of Developing or Dying of Cancer Software. In. 670 ed: Statistical Research and Applications Branch, National Cancer Institute; 2005.
4. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2010. In: National Cancer Institute, (ed). Bethesda; 2012.
5. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. In. Toronto, ON; 2015.
6. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24(11):1936-1940.
7. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-1053.
8. Johnson JA, Carstensen B, Witte D, et al. Diabetes and cancer (1): evaluating the temporal relationship between type 2 diabetes and cancer incidence. Diabetologia. 2012;55(6):1607-1618.
9. Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer I: risk, survival, and implications for screening. Cancer Causes Control. 2012;23(6):967-981.
10. Onitilo AA, Engel JM, Glurich I, et al. Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes Control. 2012;23(7):991-1008.
11. Vigneri P, Frasca F, Sciacca L, et al. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-1123.
12. Vigneri R. Diabetes: diabetes therapy and cancer risk. Nat Rev Endocrinol. 2009;5(12):651-652.
13. Deng L, Gui Z, Zhao L, et al. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Dig Dis Sci. 2012;57(6):1576-1585.
14. Flood A, Strayer L, Schairer C, et al. Diabetes and risk of incident colorectal cancer in a prospective cohort of women. Cancer Causes Control. 2010;21(8):1277-1284.
15. Godsland IF. Insulin resistance and hyperinsulinaemia in the development and progression of cancer. Clin Sci (Lond). 2010;118(5):315-332.
16. He J, Stram DO, Kolonel LN, et al. The association of diabetes with colorectal cancer risk: The Multiethnic Cohort. Br J Cancer. 2010;103(1):120-126.
17. Kramer HU, Schottker B, Raum E, et al. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. Eur J Cancer. 2012;48(9):1269-1282.
18. Limburg PJ, Anderson KE, Johnson TW, et al. Diabetes mellitus and subsitespecific colorectal cancer risks in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2005;14(1):133-137.
19. Seow A, Yuan JM, Koh WP, et al. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. J Natl Cancer Inst. 2006;98(2):135-138.
20. Sun L, Yu S. Diabetes mellitus is an independent risk factor for colorectal cancer. Dig Dis Sci. 2012;57(6):1586-1597.
21. Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: A meta-analysis. J Natl Cancer Inst. 2005;97(22):1679-1687.
22. Yuhara H, Steinmaus C, Cohen SE, et al. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106(11):1911-1921; quiz 1922.
23. Jiang Y, Ben Q, Shen H, et al. Diabetes mellitus and incidence and mortality of colorectal cancer: A systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2011;26(11):863-876.
24. Luo W, Cao Y, Liao C, et al. Diabetes mellitus and the incidence and mortality of colorectal cancer: A meta-analysis of 24 cohort studies. Colorectal Dis. 2012;14(11):1307-1312.
25. Wu L, Yu C, Jiang H, et al. Diabetes mellitus and the occurrence of colorectal cancer: an updated meta-analysis of cohort studies. Diabetes Technol Ther. 2013;15(5):419-427.
26. De Bruijn KM, Arends LR, Hansen BE, et al. Systematic review and metaanalysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. Br J Surg. 2013;100(11):1421-1429.
27. Martinez ME, Giovannucci E, Spiegelman D, et al. Leisure-time physical activity, body size, and colon cancer in women. Nurses' Health Study Research Group. J Natl Cancer Inst. 1997;89(13):948-955.
28. Giovannucci E, Ascherio A, Rimm EB, et al. Physical activity, obesity, and risk for colon cancer and adenoma in men. Ann Intern Med. 1995;122(5):327-334.
29. Colditz GA, Willett WC, Stampfer MJ, et al. Weight as a risk factor for clinical diabetes in women. Am J Epidemiol. 1990;132(3):501-513.
30. Manson JE, Rimm EB, Stampfer MJ, et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. Lancet. 1991;338(8770):774-778.
31. Salmeron J, Ascherio A, Rimm EB, et al. Dietary fiber, glycemic load, and risk of NIDDM in men. Diabetes Care. 1997;20(4):545-550.
32. Salmeron J, Manson JE, Stampfer MJ, et al. Dietary fiber, glycemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA. 1997;277(6):472-477.
33. Potter JD. Nutrition and colorectal cancer. Cancer Causes Control. 1996;7(1):127-146.
34. Satia-Abouta J, Galanko JA, Martin CF, et al. Food groups and colon cancer risk in African-Americans and Caucasians. Int J Cancer. 2004;109(5):728-736.
35. Willett W. The search for the causes of breast and colon cancer. Nature. 1989;338(6214):389-394.
36. Lipscombe L. Insulin, Insulin Resistance, and Cancer Associations. In: Fantus IG, (ed). Insulin Resistance and Cancer. New York: Springer; 2011, 111-140.
37. Asao K, Kao WH, Baptiste-Roberts K, et al. Short stature and the risk of adiposity, insulin resistance, and type 2 diabetes in middle age: The Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Diabetes Care. 2006;29(7):1632-1637.
38. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906-2912.
39. Sturmer T, Buring JE, Lee IM, et al. Metabolic abnormalities and risk for colorectal cancer in the physicians' health study. Cancer Epidemiol Biomarkers Prev. 2006;15(12):2391-2397.
40. Arem H, Pfeiffer RM, Engels EA, et al. Pre-and Postdiagnosis Physical Activity, Television Viewing, and Mortality Among Patients With Colorectal Cancer in the National Institutes of Health-AARP Diet and Health Study. J Clin Oncol. 2014; In press.
41. Kanadiya MK, Gohel TD, Sanaka MR, et al. Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopy. J Diabetes Complications. 2013;27(5):463-466.
42. Tseng CH. Diabetes, metformin use, and colon cancer: A population-based cohort study in Taiwan. Eur J Endocrinol. 2012;167(3):409-416.
43. Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: A meta-analysis. Diabetes Care. 2011;34(10):2323-2328.
44. Chang CH, Lin JW, Wu LC, et al. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology. 2012;55(5):1462-1472.
45. Lewis JD, Capra AM, Achacoso NS, et al. Thiazolidinedione therapy is not associated with increased colonic neoplasia risk in patients with diabetes mellitus. Gastroenterology. 2008;135(6):1914-1923, 1923 e1.
46. Garrett CR, Hassabo HM, Bhadkamkar NA, et al. Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer. 2012;106(8):1374-1378.
47. Lee JH, Kim TI, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer. 2012;131(3):752-759.
48. Lega IC, Shah PS, Margel D, et al. The Effect of Metformin on Mortality Following Cancer among Patients with Diabetes. Cancer Epidemiol Biomarkers Prev. 2014;23(10):1974-1984.
49. Khan NF, Mant D, Carpenter L, et al. Long-term health outcomes in a British cohort of breast, colorectal and prostate cancer survivors: A database study. Br J Cancer. 2011;105(Suppl 1):S29-S37.
50. Stava CJ, Beck ML, Feng L, et al. Diabetes mellitus among cancer survivors. J Cancer Surviv. 2007;1(2):108-115.
51. Feng JP, Yuan XL, Li M, et al. Secondary diabetes associated with 5-fluorouracil-based chemotherapy regimens in non-diabetic patients with colorectal cancer: results from a single-centre cohort study. Colorectal Dis. 2013;15(1):27-33.
52. Robles SC, Marrett LD, Clarke EA, et al. An application of capture-recapture methods to the estimation of completeness of cancer registration. J Clin Epidemiol. 1988;41(5):495-501.
53. Hux JE, Ivis F, Flintoft V, et al. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512-516.
54. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170(2):244-256.
55. Austin PC, Walraven C. The mortality risk score and the ADG score: two points-based scoring systems for the Johns Hopkins aggregated diagnosis groups to predict mortality in a general adult population cohort in Ontario, Canada. Med Care. 2011;49(10):940-947.
56. John Hopkins Bloomberg School of Public Health. The Johns Hopkins ACG® Case-Mix System. In. Reference Manual Version 7.0 ed; 2005.
57. Cohen J. Statistical power analysis for the behavioural sciences. Hillsdale, NJ: Academic Press; 1988.
58. Mamdani M, Sykora K, Li P, et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ. 2005;330(7497):960-962.
59. Neyeloff JL, Fuchs SC, Moreira LB. Meta-analyses and Forest plots using a microsoft excel spreadsheet: step-by-step guide focusing on descriptive data analysis. BMC Res Notes. 2012;5:52.
60. Tabak AG, Jokela M, Akbaraly TN, et al. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221.
61. Oyer DS, Shah A, Bettenhausen S. How to manage steroid diabetes in the patient with cancer. J Support Oncol. 2006;4(9):479-483.
62. Walker ED. Hyperglycemia. A complication of chemotherapy in children. Cancer Nurs. 1988;11(1):18-22.
63. Lipscombe LL, Chan WW, Yun L, et al. Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia. 2013;56(3):476-483.
64. Ellis ME, Weiss RB, Korzun AH, et al. Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study. Am J Clin Oncol. 1986;9(6):533-536.
65. Hickish T, Astras G, Thomas P, et al. Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst. 2009;101(7):537.
66. Public Health Agency of Canada. Diabetes in Canada: Facts and figures from a public health perspective. http://www.phac-aspc.gc.ca/cd-mc/publications/diabetes-diabete/facts-figures-faits-chiffres-2011/chap1-eng.php#Inc. Accessed December 15, 2011.
67. Snyder CF, Frick KD, Herbert RJ, et al. Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls. J Clin Oncol. 2013;31(9):1140-1148.
68. Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083-3107.